AzTrials
AzTrials

StrokeNCT06533176

Real-time Personalized Brain State-dependent TMS After Stroke

A study testing Personalized brain state-dependent single-pulse TMS in people with Stroke, run by Sara Hussain at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Transcranial magnetic stimulation (TMS) interventions could feasibly strengthen residual corticospinal tract (CST) connections and enhance recovery of paretic upper extremity function after stroke. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Stroke
What is being tested?
Personalized brain state-dependent single-pulse TMS
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
37 participants
Where
1 siteUnited States
Study dates
1 Aug 2024to Aug 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

-Presence of residual upper extremity hemiparesis, defined as any of the following: Fugl Meyer Upper Extremity Score <66, Wolf Motor Function Test Score <70, Affected hand performance on the 9-Hole Peg Test >= 10% worse than unaffected hand, Affected hand pinch, key, or power grip performance >= 10% worse than unaffected hand,

  • Occurrence of ischemic or hemorrhagic stroke >= 6 months before participation
  • Mini Mental State Exam score > 24
  • Willingness and ability to provide informed consent
  • No history of neurological disease and/or neurological injury other than stroke
  • No TMS contraindications, including but not limited to:

Cardiac pacemaker, Cochlear implant, Cortical stimulator, Deep brain stimulator, Vagus nerve stimulator, Cervical spine epidural stimulation, Ventriculoperitoneal shunt, Ferromagnetic metallic implants above the level of the seventh cervical vertebra, Seizure in the last 12 months while taking anti-epilepsy medication, History of adverse reactions to TMS or peripheral nerve stimulation, Current, suspected, or planned pregnancy, Any recent changes (within the last month) to medication use

  • Presence of residual corticospinal connections innervating an affected upper extremity muscle following stimulation of the lesioned hemisphere (i.e., MEP+), evaluated at rest

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sara J Hussain, PhD contact

319-335-1182

sara-hussain@uiowa.edu

Sara J Hussain, PhD contact

United States1 site, 1 recruiting
  • University of Iowa

    Iowa City, Iowa, 52242

    Sara Hussain, 847-309-5189, sara-hussain@uiowa.edu

    Recruiting

Other trials in United States

About this study

Official title: Towards Real-time Personalized Brain State-dependent TMS to Enhance Poststroke Hand Rehabilitation

Transcranial magnetic stimulation (TMS) interventions could feasibly strengthen residual corticospinal tract (CST) connections and enhance recovery of paretic upper extremity function after stroke. This project will test whether personalized brain state-dependent TMS can activate the residual corticospinal tract better than standard TMS, and evaluate the relationship between this activation and upper extremity motor impairment.

Read the detailed description

Transcranial magnetic stimulation (TMS) interventions could feasibly strengthen residual corticospinal connections and enhance recovery of paretic upper extremity function after stroke. To maximize the therapeutic effects of such interventions, they must be delivered during poststroke brain activity patterns during which TMS best activates the residual corticospinal tract and enhances neural transmission within it (i.e., brain state-dependent TMS). In this study, the investigators will test the feasibility of real-time, personalized brain state-dependent TMS in chronic stroke survivors. The investigators will also quantify the relationship between personalized poststroke brain state-dependent activation of the residual corticospinal tract and upper extremity motor impairment; results will inform future clinical trial inclusion criteria.

Participants will visit the laboratory for two days of testing that are separated by at least one night of sleep. On Day 1, participants will provide their informed consent. The MacArthur Competence Assessment Tool and the Frenchay Aphasia Screening Test will be used to evaluate consent capacity and confirm the presence of expressive aphasia as needed. Afterwards, the investigators will complete eligibility screening and clinical assessment of upper extremity motor impairment using the Upper Extremity Fugl-Meyer Assessment, measurements of grip and pinch strength, and a dexterity measurement that requires participants to place small pegs into round holes. Participants will then be screened for the presence of residual corticospinal connections from the lesioned hemisphere to an affected upper extremity muscle at rest. Recording electrodes will be attached to multiple affected arm muscles in order to record TMS-evoked twitches in these muscles. During this screening procedure, single-pulse TMS will be applied to each point of a 1 cm resolution grid covering primary and secondary motor areas of the lesioned hemisphere at maximum stimulator output. If TMS reliably elicits a muscle twitch in any of the recorded muscles, that participant will be considered to have residual corticospinal connections and will be eligible for the full study. If no muscle twitch can be elicited in any of these muscles, that participant will not be eligible for the full study. Afterwards, all recording electrodes will be removed and the participant will leave the laboratory.

On Day 2, participants will return to the laboratory. The investigators will place recording electrodes on the scalp using a swim-type cap. The investigators will also place recording electrodes on the most distal affected arm muscle in which a twitch was most reliably observed during Day 1 as well as four additional muscles of the affected arm. After determining the location at which TMS best elicits muscle twitches, the investigators will determine the lowest possible intensity at which TMS elicits muscle twitches at least half of the time. Then, they will deliver 6 blocks of 100 single TMS pulses while the participant rests quietly with their eyes open; stimulation will be delivered at an intensity that is 20% greater than the lowest possible intensity at which TMS elicits muscle twitches at least half of the time. Afterwards, the investigators will use the muscle and brain activity recordings acquired during these 6 blocks to build a personalized mathematical model that identifies which patterns of brain activity correspond to the largest TMS-evoked muscle twitches. The investigators will then use this model to detect the occurrence of these brain activity patterns in real-time; when these patterns are detected, single TMS pulses will be delivered. For comparison, the investigators will also deliver single TMS pulses during random brain activity patterns. Afterwards, all recording electrodes will be removed, participation will be complete, and the participant will leave the laboratory.

The investigators will recruit a total of 37 chronic stroke survivors for this study. The number of participants needed for this study was determined from their preliminary studies and previous studies that explored the relationship between variability in corticospinal tract activation (a necessary component of building robust personalized mathematical models) and corticospinal tract integrity (a correlate of motor impairment and recovery potential).

Conditions
Stroke
Being tested
Personalized brain state-dependent single-pulse TMS
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Personalized brain state-dependent single-pulse TMSDevice

    Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.

Study groups in NCT06533176
Study groupRoleWhat they receive
Brain state-dependent TMS during strong statesExperimentalNot described
Receives: Device: Personalized brain state-dependent single-pulse TMS
Brain state-dependent TMS during random statesActive comparatorNot described
Receives: Device: Personalized brain state-dependent single-pulse TMS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MEP amplitudes

    Peak-to-peak MEP amplitudes elicited by single TMS pulses delivered during personalized brain activity patterns corresponding to strong corticospinal transmission and random brain activity patterns will be measured. At the individual participant level, all MEP amplitudes will be normalized to the mean MEP amplitude observed in that participant. Mean normalized MEP amplitudes will be used to calculate the percentage MEP amplitude difference between the two brain activity patterns (i.e., strong and random).

    Measured: 1 week

  2. Upper Extremity Fugl-Meyer Assessment Scores

    Scores obtained for each participant during the Upper Extremity Fugl-Meyer Assessment will be calculated. This will provide a single impairment score that will be correlated with the percentage MEP amplitude difference between brain activity patterns reflecting strong corticospinal transmission and random brain activity patterns.

    Measured: 1 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2024
  2. Study start1 Aug 2024
  3. Primary completionAug 2026 (estimated)
  4. Study completionAug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
37 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06533176
Sponsor's protocol ID
202504299
Other IDs
R03HD114188
Status last verified
Jan 2026
First submitted
29 Jul 2024
Last updated
3 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Personalized brain state-dependent single-pulse TMS in people with Stroke, run by Sara Hussain at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sara J Hussain, PhD (319-335-1182, sara-hussain@uiowa.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MEP amplitudes (time frame: 1 week). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT06533176 | AzTrials